These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 6381248)

  • 41. [Clinical studies of BRL 28500 (clavulanic acid/ticarcillin) in the treatment of intraperitoneal infections and biliary tract infections].
    Sakai K; Ueda T; Uchino J; Hayasaka A; Shiramatsu K; Nagamachi Y; Shoda Y; Okui K; Hayata Y; Watanabe H
    Jpn J Antibiot; 1987 Apr; 40(4):759-811. PubMed ID: 3302345
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Isolated bacteria and susceptibilities to antimicrobial agents in biliary infections.
    Mukaiya M; Hirata K; Katsuramaki T; Kihara C; Kimura Y; Yamaguchi K; Furuhata T; Hata F
    Hepatogastroenterology; 2005; 52(63):686-90. PubMed ID: 15966183
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Clinical experiences with Rifamycin SV].
    Angerer M; Pexa H; Neumayr A
    Wien Med Wochenschr; 1966 Dec; 116(51):1127-31. PubMed ID: 5340059
    [No Abstract]   [Full Text] [Related]  

  • 44. Tissue penetration of moxifloxacin into human gallbladder wall in patients with biliary tract infections.
    Ober MC; Hoppe-Tichy T; Köninger J; Schunter O; Sonntag HG; Weigand MA; Encke J; Gutt C; Swoboda S
    J Antimicrob Chemother; 2009 Nov; 64(5):1091-5. PubMed ID: 19734170
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Chemotherapy of biliary tract infection (XXXII)--Excretion into bile, tissue level of the gallbladder and clinical effects of norfloxacin for biliary tract infections].
    Tanimura H; Yoshida K; Kobayashi N; Uchiyama K; Usui Y; Nishimura N; Ozawa K; Kitamura T; Izukura K; Tamura H
    Kansenshogaku Zasshi; 1987 Jun; 61(6):681-703. PubMed ID: 3119741
    [No Abstract]   [Full Text] [Related]  

  • 46. [Future of antibiotic therapy in various medical fields. 1. Internal medicine. c. Biliary tract infections].
    Urayama K; Shimada K
    Nihon Rinsho; 1984 Mar; 42(3):573-5. PubMed ID: 6381798
    [No Abstract]   [Full Text] [Related]  

  • 47. [1st clinical experiments with a new antibiotic, gentamicin].
    Pardelli G
    Minerva Med; 1967 Nov; 58(95 Suppl):4232-5. PubMed ID: 6082384
    [No Abstract]   [Full Text] [Related]  

  • 48. [Studies on the potency of action of several choleretics].
    Mörsdorf K; Wolf G
    Dtsch Med J; 1966 May; 17(10):303-6. PubMed ID: 5985421
    [No Abstract]   [Full Text] [Related]  

  • 49. [Evaluation of the clinical effectiveness of aztreonam in gram-negative infections of the biliary tract].
    Pedretti G; Magnani G
    G Ital Chemioter; 1988; 35(1-3):45-8. PubMed ID: 3256512
    [No Abstract]   [Full Text] [Related]  

  • 50. [Experimental and clinical evaluation of methacycline (Rondomycin) for biliary tract infections].
    Iwata T; Kon T; Kume Y; Fujisawa J; Kakita A
    J Antibiot B; 1967 Dec; 20(6):420-3. PubMed ID: 5301339
    [No Abstract]   [Full Text] [Related]  

  • 51. [Therapeutic aspects of functional symptoms of the upper abdomen in biliary tract diseases].
    Ardjah H
    Fortschr Med Suppl; 1991; 115():2-8. PubMed ID: 1813372
    [No Abstract]   [Full Text] [Related]  

  • 52. Gentamicin levels in the human biliary tract.
    Pitt HA; Roberts RB; Johnson WD
    J Infect Dis; 1973 Mar; 127(3):299-302. PubMed ID: 4688926
    [No Abstract]   [Full Text] [Related]  

  • 53. Antibiotics in infections of the biliary tract.
    Muller EL; Pitt HA; Thompson JE; Doty JE; Mann LL; Manchester B
    Surg Gynecol Obstet; 1987 Oct; 165(4):285-92. PubMed ID: 3310282
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Tobramycin: clinical and microbiological evaluation].
    Schoutens E; Vanderlinden MP; Yourassowsky E
    Acta Clin Belg; 1972; 27(5):578-84. PubMed ID: 4669780
    [No Abstract]   [Full Text] [Related]  

  • 55. [Clinical experiences with cefmetazole for peritonitis and biliary tract infections with special reference to excretion of cefmetazole into bile (author's transl)].
    Saito T; Yamada Y; Yokoyama S
    Jpn J Antibiot; 1979 Apr; 32(4):504-8. PubMed ID: 459081
    [No Abstract]   [Full Text] [Related]  

  • 56. [Infectious hepatobiliary diseases].
    Kunii O
    Naika; 1972; 29(2):215-21. PubMed ID: 4552440
    [No Abstract]   [Full Text] [Related]  

  • 57. [Current trends in surgical infections of the gallbladder and bile ducts].
    Guzzetti A; Premoli P
    Chir Ital; 1982 Apr; 34(2):196-224. PubMed ID: 7046970
    [No Abstract]   [Full Text] [Related]  

  • 58. [Clinical studies on apalcillin in biliary tract infections (author's transl)].
    Mishima K; Ohta T; Kitagawa N; Harada H
    Jpn J Antibiot; 1979 Sep; 32(9):960-5. PubMed ID: 501923
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Bacterial lesions of the biliary tract in viral hepatitis].
    Andreĭchin MA
    Zh Mikrobiol Epidemiol Immunobiol; 1980 Oct; (10):72-6. PubMed ID: 7003997
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Diffusion of cephazolin in the biliary tract].
    Brogard JM; Dorner M; Haegele P; Meyer C; Lavillaureix J
    Nouv Presse Med; 1974 Apr; 3(0):24-8. PubMed ID: 4600176
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.